Achieve Life Sciences (ACHV) Convertible Debt (2021 - 2026)
Achieve Life Sciences' (ACHV) quarterly Convertible Debt came in at $9.3 million in Q1 2026, up 7.68% YoY from $8.7 million in Q1 2025, and down 16.66% on a QoQ basis from $11.2 million in Q4 2025.
Achieve Life Sciences (ACHV) Convertible Debt (2021 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 6 years of Convertible Debt data on file, last reported at $9.3 million in Q1 2026.
- Quarterly Convertible Debt rose 7.68% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (up 7.68% YoY) and the FY2025 annual result came in at $11.2 million, up 13.7% from the prior year.
- Convertible Debt retreated to $9.3 million in Q1 2026, from $11.2 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $16.2 million in Q3 2023 to a low of $8.7 million in Q1 2025.
- A 5-year average of $11.8 million and a median of $9.8 million in 2024 frame the typical range for Convertible Debt.
- Annual changes were most pronounced in 2024 — Convertible Debt tumbled 44.03% — and 2025, when it gained 13.7%.
- Tracing ACHV's Convertible Debt over 5 years: stood at $15.8 million in 2022, then advanced by 2.74% to $16.2 million in 2023, then plunged by 39.26% to $9.8 million in 2024, then grew by 13.7% to $11.2 million in 2025, then slipped by 16.66% to $9.3 million in 2026.
- The last three Convertible Debt figures came in at $9.3 million (Q1 2026), $11.2 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.46 Mn |
| Mar 31, 2026 | 9.32 Mn |
| Dec 31, 2025 | 11.19 Mn |
| Sep 30, 2025 | 8.67 Mn |
| Jun 30, 2025 | 8.66 Mn |
| Mar 31, 2025 | 8.66 Mn |
| Dec 31, 2024 | 9.84 Mn |
| Sep 30, 2024 | 9.82 Mn |
| Jun 30, 2024 | 8.80 Mn |
| Sep 30, 2023 | 16.20 Mn |
| Jun 30, 2023 | 15.73 Mn |
| Sep 30, 2022 | 15.76 Mn |
| Jun 30, 2022 | 15.46 Mn |
| Mar 31, 2022 | 15.17 Mn |
| Dec 31, 2021 | 14.92 Mn |